 |
|
 |
|
|
 |
|||
       |
|||
|
|||
 |
|||
|
|||
Segment Results - 1st Quarter Fiscal Year 2006
- TECHNE Corporation and Subsidiaries
- Hematology Division
- Biotechnology Division
- R&D Systems Europe (in £'s)
- R&D Systems Europe (in $'s)
- Corporate and Other
(in thousands of $’s, except
per share data)
| Fiscal 2006 | Increase(Decrease) From Fiscal 2005 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 47,709 | 100% | 6,790 |
| Cost of sales | 11,096 | 23% | 2,209 |
| Gross margin | 36,613 | 77% | 4,581 |
| Gross margin percentage | 76.7% | ||
| SG&A expense | 6,454 | 14% | 820 |
| R&D expense | 4,717 | 10% | 29 |
| Amortization expense | 492 | 1% | 187 |
| Interest expense | 223 | -- | (22) |
| Interest income | (974) | (2%) | 79 |
| Othernon-operating exp., net | 211 | -- | (255) |
| 11,123 | 23% | 838 | |
| Earnings before income taxes | 25,490 | 54% | 3,743 |
| Income taxes | 8,489 | 18% | 934 |
| 17,001 | 36% | 2,809 | |
| Diluted earnings per share | 0.43 | ||
| Weighted average diluted shares outstanding | 39,669 | ||
Back to Top
(in thousands of $’s)
| Fiscal 2006 | Increase(Decrease) From Fiscal 2005 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 3,534 | 100% | (479) |
| Cost of sales | 2,105 | 60% | (115) |
| Gross margin | 1,429 | 40% | (364) |
| Gross margin percentage | 40.4% | ||
| SG&A expense | 384 | 11% | (25) |
| R&D expense | 185 | 5% | (3) |
| Interest, net | (37) | (1%) | 19 |
| 532 | 15% | (9) | |
| Pretax result | 897 | 25% | (355) |
Back to Top
(in thousands of $’s)
| Fiscal 2006 | Increase(Decrease) From Fiscal 2005 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 37,599 | 100% | 6,908 |
| Intersegment sales | (5,299) | (495) | |
| 32,300 | 6,413 | ||
| Cost of sales | 8,470 | 23% | 2,359 |
| Intersegment sales | (5,323) | (567) | |
| 3,147 | 1,792 | ||
| Gross margin | 29,153 | 77% | 4,621 |
| Gross margin percentage | 77.5% | ||
| SG&A expense | 3,639 | 10% | 666 |
| R&D expense | 4,532 | 12% | 32 |
| Amortization expense | 492 | 1% | 187 |
| Interest, net | (268) | (1%) | 146 |
| 8,395 | 22% | 1,031 | |
| Pretax result | 20,758 | 55% | 3,590 |
(1) Fiscal 2006 includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.
Back to Top
(in thousands of £'s)
| Fiscal 2006 | Increase(Decrease) From Fiscal 2005 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 6,690 | 100% | 610 |
| Cost of sales | 3,292 | 50% | 361 |
| Gross margin | 3,398 | 50% | 249 |
| Gross margin percentage | 50.8% | ||
| SG&A expense | 1,004 | 15% | 54 |
| Interest income | (326) | (5%) | (72) |
| Exchange loss/(gain) | 15 | -- | (11) |
| 693 | 10% | (29) | |
| Pretax result | 2,705 | 40% | 278 |
Back to Top
(in thousands of $’s)
| Fiscal 2006 | Increase(Decrease) From Fiscal 2005 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 11,875 | 100% | 856 |
| Cost of sales | 5,844 | 50% | (71) |
| Gross margin | 6,031 | 50% | 324 |
| Gross margin percentage | 50.8% | ||
| SG&A expense | 1,782 | 15% | 60 |
| Interest income | (579) | (5%) | (119) |
| Exchange loss | 28 | -- | (19) |
| 1,231 | 10% | (78) | |
| Pretax result | 4,800 | 40% | 402 |
Back to Top
(in thousands of $’s)
| Fiscal 2005 | Increase(Decrease) From Fiscal 2005 | |
| First Quarter | First Quarter | |
| Interest income | 90 | 48 |
| Rental income | 342 | 323 |
| 432 | 371 | |
| SG&A expense | 649 | 119 |
| Interest expense | 223 | 59 |
| Other-Hemerus losses | 82 | 79 |
| Other-Building expenses | 443 | 8 |
| 1,397 | 265 | |
| Pretax result | (965) | 106 |
Back to Top
(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC